Israeli stocks and shares have been buffeted as in most other countries. The shekel has suffered a 15% devaluation against the dollar, but has increased in value against most other major currencies. So, where to put your money?

Yesterday, I raised an interesting solution with a senior local financier. Our survey led us to believe that most investment possibilities today are either risky or bear little interest or both. However, if you are seeking a long-term bet, there is an alternative.

Israel start ups have seen great success over the past decade. HP, Boston Scientific, Microsoft have all made significant purchases of small dynamos from Tel Aviv and Herzylia. And the Israeli brain is still churning out new, exciting technologies, pointing to healthy revenue streams in the future.

For example, I have been working closely with CEPCO. Based in Hod Hasharon, they have developed a software, which is embedded on to a smart card with a USB application. This allows the card to collect, manage and export in a secure manner up to 32 GB of info – text, video, Xray and more. 

The first application of this platform has been directed to the medical care market. Citizens will own and possess in their pocket all their medical records, a dream for health funds until now.

What makes CEPCO interesting to an investor is not just that it has completed its r&d. An influential senior civil servant working intimately with German government health funds has welcomed the technology, opening up the CEPCO to a multi-million Euro market. Long-term funding will thus be secured, along with a partnership from the NAV, a German doctor’s association.

Dr Gunter Pollanz, the founder and chairman of CEPCO, told me that all that was missing was an immediate injection of Euro 300,000. This will create a subsiduary in Germany and a small software team for customization.

CEPCO is probably typical of many other companies in Israel, carrying on despite the tsunami sweeping world finacial markets. Savvy investors could do worse than look at such possibilites, especially while the safe blue chip altenatives like banks and insurance firms struggle to return back to base.